4-Methoxybutyrfentanyl Stats & Data

4-MeO-BF is a highly potent ‘research’ fentanyl-type opioid first identified in Europe in 2015. Clinically confirmed intoxications have shown life-threatening opioid toxicity at low ng/mL serum levels, consistent with fentanyl-class potency. Purity and composition of unregulated opioid products vary widely, and mixtures with multiple high‑potency opioids or sedatives are increasingly common; use volumetric dosing, avoid redosing quickly, and never eyeball. Metered nasal sprays or precisely diluted oral solutions (e.g., ≤1 mg/mL) with 0.01 mL syringes can reduce dosing error. Naloxone reverses toxicity but has shorter action than many opioids; repeated doses or continuous infusion and cardiorespiratory monitoring are often required; re‑narcotisation within 20–60 min is well described. Combining with benzodiazepines, alcohol, GHB/GBL, barbiturates, pregabalin/gabapentin, or sedating antipsychotics markedly increases respiratory depression risk. Opioid + stimulant (“speedball”) may mask sedation while respiratory depression progresses—avoid. Serotonin toxicity has been reported with fentanyl combined with SSRIs/SNRIs or MAO‑Is; use extra caution if on serotonergic medicines. Accidental occupational exposure to powders/aerosols of fentanyl analogues is a recognised risk for labs and responders; wear appropriate PPE and have naloxone available when handling bulk material. Because duration is short, frequent redosing is a major driver of overdose—plan set/setting, avoid using alone, carry naloxone, and prioritise oxygen/ventilation in emergencies.